Cambridge Healthtech Institute’s Inaugural

Clinical Cancer Immunotherapy

Translating Cancer Therapy from Promise to Reality

February 19-20, 2015 | The InterContinental San Francisco | San Francisco, CA
Part of the 22nd International Molecular Medicine Tri-Conference


About this Symposium:

There is a great need for more effective and less toxic therapies for metastatic cancer patients. Advances in genetically engineered T cells is demonstrating clinical efficacy, eliminating many side effects from traditional chemo- and radiation therapies. Cambridge Healthtech Institute's Inaugural Clinical Cancer Immunotherapy symposium will demonstrate bench to bedside translation of combination immunotherapies, adoptive T cell therapies, as well as molecular targeted therapies. Case studies using prognostic biomarkers to predict immunotherapy response will also be showcased. The human immune system is inherently capable of recognizing and destroying cancer cells. At this event, attendees will learn more about the translational advances that are converting the promise of immunotherapy into reality for cancer treatment.


Monitoring Immune Competence by Mass Cytometry

Holden T. Maecker, Ph.D., Associate Professor (Research), Microbiology & Immunology, Stanford University

Type 1 Immunity as a Biomarker for Clinical Response to Immune Therapy of Cancer

William (Bill) Watt, Ph.D., University of Washington Tumor Vaccine Group; CEO & Co-Founder, EpiThany Inc.

Searching for Tumor-Specific Antigens

Qi Zhao, Ph.D., Assistant Investigator, Ludwig Collaborative Laboratory, Department of Neurosurgery, Johns Hopkins University

Functional Analysis of Disease and Treatment-Associated Changes in Immune Cell and Network Signaling Using Single Cell Network Profiling

Rachael E. Hawtin, Ph.D., VP & Head, Research, Nodality

Strategies for Improving the Reporting of Human Immunophenotypes

Allan B. Dietz, Ph.D., Scientific Director, Human Cell Therapy Lab; Assistant Professor, Experimental Pathology, Immunology, Mayo Clinic


Immunologic Targeting of Therapy Resistant Cancers

Michael Morse, M.D., MHS, FACP, Professor, Medicine, Medical Oncology, Duke University Medical Center

Characterizing the Local Tumor Microenvironment to Develop Rational Treatment Combinations

Janis Taube, M.D., MSc., Director, Dermatopathology; Assistant Professor, Dermatology and Pathology, Johns Hopkins


Activation of iNKT Cells by NKTT320 as an Approach to Cancer Immunotherapy

Robert Mashal, Ph.D., CEO, NKT Therapeutics

Pembrolizumab Program in Melanoma

Scot W. Ebbinghaus, Executive Director, Clinical Research, Merck

For more details on the conference, please contact: 
Samantha Lewis
Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5461

For partnering and sponsorship information, please contact:
Jon Stroup (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483

Joseph Vacca (Companies L-Z)
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431


  2015 Plenary Sessions 

2015 MMTC Prelim Agenda 

Premier Sponsors:


Jackson Laboratory - small logo 

Leica Biosystems 




Thomson Reuters-Large 

Local Partners:




City of SSF